04

August, 2021

Is Teladoc Oversold? (TDOC)

Share on facebook
Share on twitter
Share on linkedin

Is Teladoc Oversold? (TDOC)

A combination of weaker-than-expected earnings and swelling re-opening optimism caused shares of the telehealth company, Teladoc (TDOC), to fall by more than -50% from the ATH levels seen earlier this year. … But has the sell-off been overstated?
 
LikeFolio data still suggests a longer-term bullish outlook, as underlying Purchase Intent Mentions have remained significantly higher than 2019: +64% higher in 21Q2 (ended 6/30)
Although PI Mention volume declined -61% from last year’s lockdown highs, that surge in usage may prove beneficial for long-term adoption…Generic Telehealth Mentions are trending +792% vs. 2019 (90-day moving average), demonstrating a lasting impact on consumer demand for such services.
 
Despite missing EPS estimates, Teladoc reported better-than-expected 21Q2 revenues last week and raised full-year guidance – After opening lower, TDOC shares rallied +14% in the following trading day.

Stay ahead of wallstreet, take a tour/buy now.

Get a demo at your own pace and see the power of LikeFolio data & insights for yourself.  Let’s do this!

Sign Up For Our Daily Insights

Fill in your name & email to download your complimentary report.